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Myasthenia gravis is a rare but 
treatable disease
To the Editor: Myasthenia gravis (MG) is a rare but treatable disease. 
Early recognition and treatment can prevent mortality and morbidity, 
thereby reducing the burden of the disease. In 85 - 90% of cases, the 
diagnosis is made with an acetylcholine receptor antibody (AChR) 
radioimmunoprecipitation assay. As a diagnostic test, the assay is 
99.9% specific for the presence of MG.[1] We recently reported the 
incidence of AChR-positive MG in South Africa (SA) based on all 
the laboratory data over a 2-year period (2011 - 2012).[2] Here, we 
highlight two issues emanating from that research of importance to 
specialist services delivery and MG management. 
The first issue relates to the need to improve diagnostic capacity 
for neurological disorders in regions with limited resources. Our 
results showed an annual crude incident rate of 8.5 per million for 
AChR-positive MG, which is comparable with the pooled estimate of 
7.3 per million from a worldwide systematic study,[3] and represents 
an apparent increase in incidence from 2.6 per million reported in 
2004.[4] Rather than indicating an increased incidence, we believe 
the observed increase represents improved diagnostic capacity in the 
form of improved access to the assay, as well as better recognition of 
the disease. Diagnostic capacity has increased thanks to a number of 
SA universities establishing outreach programmes, increasing access 
to specialist services. Still, MG is currently diagnosed mostly in 
provinces with more resources (Fig. 1). 
The second issue relates to the efficient use of resources in 
MG management. We found that ~10% of requests were repeat 
antibody tests. Some clinicians are routinely tracking antibody 
titres to monitor disease activity. There is currently poor evidence 
to suggest that the AChR antibody test is the preferred biomarker 
for disease activity compared with bedside clinical assessments. 
Constantly changing conditions in the laboratory, such as variations 
in temperature, etc., materially affect assay results. Therefore assay 
result A performed at time 1 cannot accurately be compared with 
assay result B performed at a different time. Scientific experimental 
methods would require samples A and B to be performed in the 
same assay for comparative purposes. In such an experiment using 
stored samples collected in a prospective MG treatment trial, a fall 
in antibody titres correlated weakly with improvement as assessed 
by two validated clinical outcome measures.[5] This study also 
compared serial measurements of AChR titres in an observational 
cohort performed at least 6 months apart and at separate times, 
and found even less correlation between clinical improvement and 
change in titres. Indeed, the conclusion was that a clinical assessment 
tool provided a more effective measure to monitor response to 
therapy. The MG composite score is a good example of a simple 
clinical tool that can be used to monitor patients. It is a validated 
instrument that takes 5 minutes to perform, and includes ocular, 
bulbar, respiratory and proximal muscle strength evaluations.[6] The 
bulbar and respiratory items are largely based on patient symptoms. 
In contrast, each commercial AChR antibody test costs ~ZAR1 000. 
In conclusion, our recent work suggests that the overall incidence 
rate of MG in our population is comparable with rates reported in 
North American and European studies in keeping with a biological 
rather than environmental aetiology for MG. The geographical 
variation of the incidence rate within the country underscores 
the importance of outreach programmes in regions with limited 
resources. Finally, when managing a chronic disease such as MG, 
it is preferable to treat the patient’s symptoms rather than rely on 
an expensive laboratory test that cannot be accurately interpreted 
outside a rigorous scientific experiment. 
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Fig. 1. Average incidence ratios for AChR-antibody-positive myasthenia 
gravis in SA between 2011 and 2012, by province. The number of practising 
neurologists per province as of December 2012 is shown. Incidence rates 
calculated using denominators from the 2011 census and 2012 adjusted 
population estimates (www.statssa.gov.sa).
